Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction - 12/08/11
Reprint requests: David Westaby, MA, FRCP, Department of Gastroenterology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, Du Cane Road, London W12 0HS, United KingdomRésumé |
Background |
In unresectable malignant bile duct obstruction in a patient with a life expectancy longer than 3 months, the use of self-expandable metal stents (SEMSs) is the standard technique to ensure continued biliary drainage. As many as 50% of patients with SEMSs will present with stent occlusion within 6 months. Changes to stent design and composition and concomitant therapy have failed to improve stent patency; therefore, alternative techniques to safely prolong stent patency are required.
Objective |
To demonstrate the safety of endobiliary bipolar radiofrequency ablation (RFA) in patients with malignant biliary obstruction and to report the 90-day biliary patency of this novel procedure.
Design |
Open-label pilot study.
Setting |
Single tertiary care unit.
Patients |
A total of 22 patients with unresectable malignant bile duct obstruction.
Interventions |
Bipolar RFA within the bile duct.
Main Outcome Measurements |
Immediate and 30-day complications and 90-day stent patency.
Results |
A total of 22 patients (16 pancreatic, 6 cholangiocarcinoma) were recruited between January 2009 and April 2010. Deployment of an RFA catheter was successful in 21 patients. SEMS placement was achieved in all cases of successful RFA catheter deployment. One patient failed to demonstrate successful biliary decompression after SEMS placement and died within 90 days. All other patients maintained stent patency at 30 days. One patient had asymptomatic biochemical pancreatitis, 2 patients required percutaneous gallbladder drainage, and 1 patient developed rigors. At 90-day follow-up, 1 additional patient had died with a patent stent, and 3 patients had occluded biliary stents.
Limitations |
Cohort study.
Conclusions |
Endobiliary RFA treatment appears to be safe. Randomized studies with prolonged follow-up are warranted.
Le texte complet de cet article est disponible en PDF.Abbreviations : RFA, SEMS
Plan
| DISCLOSURE: The following authors disclosed financial relationships relevant to this publication: Ms. Nicholls: stockholder and board member of EMcision Ltd UK; Dr. Habib: stockholder and board member of EMcision Ltd UK. The other authors disclosed no financial relationships relevant to this publication. |
|
| If you would like to chat with an author of this article, you may contact Dr Westaby at David.Westaby@imperial.nhs.uk. |
Vol 73 - N° 1
P. 149-153 - janvier 2011 Retour au numéro
Article précédent
- A novel antireflux metal stent for the palliation of biliary malignancies: a pilot feasibility study (with video)
- Bing Hu, Tian-Tian Wang, Zhi-Mei Shi, Shu-Zhi Wang, Rui Lu, Ya-Min Pan, Hui Huang, Shu-Ping Wang
- Medication-induced esophageal tattoo in a patient with eosinophilic esophagitis
- Matthew N. Thoma, Alison Schneider
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?